Table 2.
Psychosis risk by medications (intrasubject comparison)
| |
Total |
|
Age <70y |
|
Age > = 70y |
|
||
|---|---|---|---|---|---|---|---|---|
| Adjusted HR* (95% CI) | P Value | Adjusted HR* (95% CI) | P Value | Adjusted HR* (95% CI) | P Value | |||
| Drugs |
L-Dopa |
Per 100 mg /day |
0.92(0.79-1.07) |
0.27 |
1.06(0.85-1.32) |
0.59 |
0.82(0.67-1.00) |
0.05 |
| DA agonists |
Per 100 mg(LDED) /day |
1.25(0.88-1.77) |
0.20 |
0.85(0.51-1.42) |
0.53 |
1.65(1.02-2.66) |
0.035 |
|
| Amantadine |
Per 50 mg /day |
0.87(0.75-1.02) |
0.08 |
0.76(0.55-1.05) |
0.09 |
0.86(0.63-1.17) |
0.33 |
|
| Selegiline |
Per 2.5 mg /day |
1.06(0.85-1.33) |
0.590 |
0.88(0.64-1.21) |
0.42 |
1.24(0.76-2.01) |
0.39 |
|
| Anti-cholinergics |
Use |
19.7(2.39-163) |
0.006 |
0.80(0.38-1.68) |
0.55 |
188.4(13.91-2551) |
<0.0001 |
|
| |
Not use (Ref) |
1 |
|
1 |
|
1 |
|
|
| Donepezil use |
Use |
0.48(0.27-0.85) |
0.012 |
0.79(0.51-1.22) |
0.29 |
0.28(0.08-1.01) |
0.051 |
|
| |
Not use (Ref) |
1 |
|
1 |
|
1 |
|
|
| Interaction | Anti-cholinergics X duration | 0.76 | (0.64-0.89) | 0.001 | 0.62(0.50-0.77) | <0.0001 | ||
Dopa were expressed as adjusted values including concomitant entacapone.
*HR was adjusted for age, sex, mH-Y (1-3 vs 4-5), MMSE (= < 24 vs >24) and duration of PD, using a generalized estimating equation.
HR was calculated for Dopa (100 mg/d, adjusted), DA agonist (LDED, 100 mg/d), selegiline (2.5 mg/d), amantadine (50 mg/d), anti-cholinergics (use vs not use), and donepezil (use vs not use).
Hazard period: prescription at psychosis occurrence.
Control period: prescription 1 month and 3 months before psychosis occurrence.